Cytek Biosciences, Inc.
CTKB
$4.11
-$0.065-1.56%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -5.58M | -11.40M | 9.64M | 940.00K | -10.43M |
| Total Depreciation and Amortization | 2.99M | 2.88M | 2.74M | 2.81M | 2.48M |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 3.49M | 5.36M | -4.89M | 6.21M | 6.05M |
| Change in Net Operating Assets | -785.00K | 3.03M | -5.50M | 3.26M | 8.11M |
| Cash from Operations | 108.00K | -125.00K | 2.00M | 13.22M | 6.20M |
| Capital Expenditure | -1.58M | -849.00K | -894.00K | -1.01M | -1.05M |
| Sale of Property, Plant, and Equipment | 23.00K | 33.00K | 191.00K | 21.00K | 76.00K |
| Cash Acquisitions | -- | -- | -471.00K | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -14.86M | 10.27M | -62.26M | -14.82M | 3.00M |
| Cash from Investing | -16.41M | 9.45M | -63.43M | -15.81M | 2.02M |
| Total Debt Issued | 1.39M | 690.00K | 2.79M | 5.00K | -3.00K |
| Total Debt Repaid | -142.00K | -1.52M | -139.00K | -140.00K | -139.00K |
| Issuance of Common Stock | 767.00K | 39.00K | 835.00K | 147.00K | 1.23M |
| Repurchase of Common Stock | -4.61M | -10.76M | -7.12M | -12.10M | -2.80M |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -2.60M | -11.55M | -3.64M | -12.08M | -1.71M |
| Foreign Exchange rate Adjustments | -921.00K | -1.23M | 1.52M | -943.00K | 2.26M |
| Miscellaneous Cash Flow Adjustments | -1.00K | -- | -- | -- | -- |
| Net Change in Cash | -19.83M | -3.45M | -63.56M | -15.62M | 8.78M |